Skip to main content
ANIP
NASDAQ Life Sciences

ANI Pharmaceuticals Reports Strong Q1 Growth, $100M Buyback, and New Licensing Revenue

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$88.4
Mkt Cap
$1.91B
52W Low
$56.71
52W High
$99.5
52W Position info
56% above low
Off High info
11% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

ANIP sits 56% above its 52-week low of $56.71.

Summary

ANI Pharmaceuticals reported strong first-quarter 2026 financial results, including significant revenue and net income growth, alongside the authorization of a $100 million share repurchase program and new licensing revenue.


Key Events · Earnings and Guidance · ANIP

  • Strong Q1 2026 Financial Performance

    Net revenues increased by 20.5% to $237.5 million, and net income grew by 88.1% to $29.5 million, resulting in diluted EPS of $1.28 for the three months ended March 31, 2026, compared to the same period in 2025.

  • Significant Share Repurchase Program Authorized

    The Board of Directors approved a share repurchase program authorizing the company to repurchase up to $100.0 million of its common stock, representing a substantial commitment to shareholder value.

  • Growth in Rare Disease Segment

    Net revenues from the Rare Disease and Brands segment increased by 36.3% to $128.2 million, primarily driven by a 42.1% increase in Cortrophin Gel sales and a 19.5% increase in ILUVIEN and YUTIQ sales.

  • New Licensing Revenue Stream

    The company recognized $15.0 million from an upfront license fee and approximately $6.5 million in initial royalties from the Harmony Agreement, contributing to the overall revenue growth.


Analysis · ANIP · Life Sciences

ANI Pharmaceuticals delivered robust first-quarter results, significantly exceeding prior year performance with strong revenue and net income growth. The company's Rare Disease segment, particularly Cortrophin Gel, was a key driver of this growth. The authorization of a substantial $100 million share repurchase program signals management's confidence and commitment to returning value to shareholders. Additionally, a new licensing agreement contributed a notable $21.5 million in upfront and royalty revenue. While several insiders adopted Rule 10b5-1 trading plans for future share sales, these are pre-planned and less indicative of immediate sentiment compared to open market transactions. This filing provides comprehensive details supporting the positive financial outlook previously indicated in a concurrent 8-K.

How filings like this one have moved

In the 30 days to Nov 9, 2026, 47.1% of the 1533 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ANIP was trading at $88.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $56.71 to $99.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ANIP - Latest Insights

ANIP
Nov 05, 2026, 5:13 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $69.00
Real-time Price: $67.41 info
Change: -$1.59 (-2%) info
Market Cap: $1.548B info
ANIP
Nov 05, 2026, 6:58 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $75.00
Real-time Price: $67.41 info
Change: -$7.59 (-10%) info
Market Cap: $1.548B info
ANIP
Nov 05, 2026, 6:56 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $71.72
Real-time Price: $67.41 info
Change: -$4.31 (-6%) info
Market Cap: $1.548B info
ANIP
Nov 05, 2026, 6:51 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $72.00
Real-time Price: $67.41 info
Change: -$4.59 (-6%) info
Market Cap: $1.548B info
ANIP
Nov 05, 2026, 1:33 AM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $72.00
Real-time Price: $67.41 info
Change: -$4.59 (-6%) info
Market Cap: $1.548B info